Here are the DEF 14A proxy statements from Phathom Pharmaceuticals, Inc. (PHAT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow PHAT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PHAT filings page.
Phathom Pharmaceuticals, Inc. is soliciting proxies for its 2026 annual stockholder meeting, to be held virtually on May 19, 2026 at 9:00 a.m. Eastern Time. Stockholders of record at the close of business on March 23, 2026, when 79,430,117 common shares were outstanding, may vote.
Stockholders will vote on electing three Class I directors to terms ending at the 2029 meeting, ratifying Ernst & Young LLP as independent auditor for 2026, and approving named executive officer compensation on a non-binding advisory “say‑on‑pay” basis. The proxy describes board composition, committee structures, director independence, director and committee retainers, equity grants, and significant stockholders’ ownership, as well as detailed voting procedures and the treatment of abstentions and broker non‑votes.